821 related articles for article (PubMed ID: 29225305)
1. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
6. γ-Secretase and its modulators: Twenty years and beyond.
Xia W
Neurosci Lett; 2019 May; 701():162-169. PubMed ID: 30763650
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for Alzheimer's disease in clinical trials.
Godyń J; Jończyk J; Panek D; Malawska B
Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364
[TBL] [Abstract][Full Text] [Related]
8. [Development of Disease-modifying Therapy for Alzheimer's Disease].
Akiyama H
Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
[TBL] [Abstract][Full Text] [Related]
9. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
Golde TE
J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
[TBL] [Abstract][Full Text] [Related]
10. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
[TBL] [Abstract][Full Text] [Related]
11. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease: emerging trends in small molecule therapies.
Mohamed T; Rao PP
Curr Med Chem; 2011; 18(28):4299-320. PubMed ID: 21861820
[TBL] [Abstract][Full Text] [Related]
14. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
15. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
Cho JE; Kim JR
Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
[TBL] [Abstract][Full Text] [Related]
16. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
Abe K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
18. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
19. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
20. Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies.
Vijayan D; Chandra R
Curr Drug Targets; 2020; 21(2):148-166. PubMed ID: 31385768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
